2-(4-acetylphenoxy)-N,N-dimethylacetamide | 731821-83-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-acetylphenoxy)-N,N-dimethylacetamide
• 英文别名: 2-(4-acetyl-phenoxy)-N,N-dimethyl-acetamide
• CAS: 731821-83-3
• 化学式: C₁₂H₁₅NO₃
• mdl: MFCD04628567
• 分子量: 221.256
• InChiKey: KOQVBLNNUYSLCR-UHFFFAOYSA-N

物化性质

• 沸点：
  390.2±22.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-acetylphenoxy)-N,N-dimethylacetamide 、 邻甲氧基苯甲醛 在 lithium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.25h， 以100%的产率得到(E)-2-(4-(3-(2-methoxyphenyl)acryloyl)phenoxy)-N,N-dimethylacetamide
  参考文献：
  名称：

  A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model

  摘要：

  Alzheimer's disease is a common neurodegenerative disease characterized by progressive degeneration and neuronal cell death, resulting in neural network dysfunction. As the underlying mechanisms, oxidative damage and neuroinflammation have been reported to contribute to the onset and deterioration of Alzheimer's disease. The nuclear factor E2-related factor 2-antioxidant responsive element signaling pathway is a pivotal cellular defense mechanism against oxidative stress. Nrf2, a transcription factor, regulates the cellular redox balance and is primarily involved in anti-inflammatory responses. In this study, we synthesized novel chalcone derivatives and found a highly potent Nrt2 activator, compound 20a. Compound 20a confirmed to activate Nrf2 and induce expression of the Nrf2-dependent enzymes HO-1 and GCLC at both mRNA and protein levels. It also suppressed the production of nitric oxide and downregulated inflammatory mediators in BV-2 microglial cells. We found that compound 20a effectively increased the expression level and the activity of superoxide dismutase in both BV-2 microglial cells and brain hippocampus region of the scopolamine-induced mouse model. In addition, compound 20a effectively recovered the learning and memory impairment in a scopolamine-induced mouse model. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111777
• 作为产物：
  描述：

  对羟基苯乙酮 在 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 20.17h， 生成 2-(4-acetylphenoxy)-N,N-dimethylacetamide
  参考文献：
  名称：

  A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model

  摘要：

  Alzheimer's disease is a common neurodegenerative disease characterized by progressive degeneration and neuronal cell death, resulting in neural network dysfunction. As the underlying mechanisms, oxidative damage and neuroinflammation have been reported to contribute to the onset and deterioration of Alzheimer's disease. The nuclear factor E2-related factor 2-antioxidant responsive element signaling pathway is a pivotal cellular defense mechanism against oxidative stress. Nrf2, a transcription factor, regulates the cellular redox balance and is primarily involved in anti-inflammatory responses. In this study, we synthesized novel chalcone derivatives and found a highly potent Nrt2 activator, compound 20a. Compound 20a confirmed to activate Nrf2 and induce expression of the Nrf2-dependent enzymes HO-1 and GCLC at both mRNA and protein levels. It also suppressed the production of nitric oxide and downregulated inflammatory mediators in BV-2 microglial cells. We found that compound 20a effectively increased the expression level and the activity of superoxide dismutase in both BV-2 microglial cells and brain hippocampus region of the scopolamine-induced mouse model. In addition, compound 20a effectively recovered the learning and memory impairment in a scopolamine-induced mouse model. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111777

文献信息

• [EN] SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE<br/>[FR] PYRROLIDINONE SUBSTITUÉE EN TANT QU'INHIBITEURS DE LA POLYMÉRASE DU VIRUS DE L'HÉPATITE C NS5B, COMPOSITION PHARMACEUTIQUE LA COMPRENANT ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：VIVALIS

  公开号：WO2011004018A1

  公开（公告）日：2011-01-13

  The present invention concerns a substituted pyrrolidinone of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof:(I), for the treatment of hepatitis C.

  本发明涉及以下式I的取代吡咯烷酮或其盐、溶剂合物、互变异构体、同位素、对映体、非对映异构体或其外消旋混合物，用于治疗丙型肝炎。
• 10a-Azalide Compound
  申请人：Sugimoto Tomohiro

  公开号：US20090281292A1

  公开（公告）日：2009-11-12

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  【目标】提供一种具有新结构的化合物，对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物，其化学式为（I），其药学上可接受的盐或其溶剂化物，或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性，因此可以作为治疗传染病的药物。
• SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE
  申请人：Berecibar Amaya

  公开号：US20120189579A1

  公开（公告）日：2012-07-26

  The present invention concerns a substituted pyrrolidinone of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: (I), for the treatment of hepatitis C.

  本发明涉及以下式I的取代吡咯烷酮或其盐、溶剂合物、互变异构体、同位素、对映异构体或其外消旋混合物，用于治疗丙型肝炎。
• 10a-AZALIDE COMPOUND
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1985620A1

  公开（公告）日：2008-10-29

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  [目的]：提供一种具有新型结构的化合物，该化合物对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌有效。 [解决方案］一种由式（I）代表的新型 10a-azalide 化合物、其药学上可接受的盐或其溶液，或制备其的中间体。本发明的化合物对流感嗜血杆菌、耐红霉素肺炎球菌等具有优异的抗菌活性，因此可用作传染性疾病的治疗剂。
• US8097708B2
  申请人：——

  公开号：US8097708B2

  公开（公告）日：2012-01-17